These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15466390)

  • 1. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.
    Kamijo A; Sugaya T; Hikawa A; Okada M; Okumura F; Yamanouchi M; Honda A; Okabe M; Fujino T; Hirata Y; Omata M; Kaneko R; Fujii H; Fukamizu A; Kimura K
    Am J Pathol; 2004 Oct; 165(4):1243-55. PubMed ID: 15466390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice.
    Kamijo-Ikemori A; Sugaya T; Matsui K; Yokoyama T; Kimura K
    Nephrology (Carlton); 2011 Aug; 16(6):539-44. PubMed ID: 21504508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage.
    Kamijo A; Kimura K; Sugaya T; Yamanouchi M; Hase H; Kaneko T; Hirata Y; Goto A; Fujita T; Omata M
    Kidney Int; 2002 Nov; 62(5):1628-37. PubMed ID: 12371963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage.
    Yokoyama T; Kamijo-Ikemori A; Sugaya T; Hoshino S; Yasuda T; Kimura K
    Am J Pathol; 2009 Jun; 174(6):2096-106. PubMed ID: 19435794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary liver type fatty acid binding protein in diabetic nephropathy.
    Kamijo-Ikemori A; Sugaya T; Ichikawa D; Hoshino S; Matsui K; Yokoyama T; Yasuda T; Hirata K; Kimura K
    Clin Chim Acta; 2013 Sep; 424():104-8. PubMed ID: 23727660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction.
    Kamijo-Ikemori A; Sugaya T; Obama A; Hiroi J; Miura H; Watanabe M; Kumai T; Ohtani-Kaneko R; Hirata K; Kimura K
    Am J Pathol; 2006 Oct; 169(4):1107-17. PubMed ID: 17003471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.
    Zuo N; Suzuki Y; Sugaya T; Osaki K; Kanaguchi Y; Wang L; Tomino Y
    Nephrol Dial Transplant; 2011 Jul; 26(7):2127-37. PubMed ID: 21109611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human liver-type fatty acid-binding protein protects against tubulointerstitial injury in aldosterone-induced renal injury.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Hoshino S; Katayama K; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F114-21. PubMed ID: 25339700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy.
    Hofstra JM; Deegens JK; Steenbergen EJ; Wetzels JF
    Nephrol Dial Transplant; 2008 Oct; 23(10):3160-5. PubMed ID: 18403431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
    Kamijo-Ikemori A; Ichikawa D; Matsui K; Yokoyama T; Sugaya T; Kimura K
    Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of L-type fatty acid-binding protein (L-FABP) in proximal tubular cells against glomerular injury in anti-GBM antibody-mediated glomerulonephritis.
    Kanaguchi Y; Suzuki Y; Osaki K; Sugaya T; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2011 Nov; 26(11):3465-73. PubMed ID: 21525165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of intravascular contrast media on urinary excretion of liver fatty acid-binding protein].
    Ohta S; Ishimitsu T; Minami J; Ono H; Matsuoka H
    Nihon Jinzo Gakkai Shi; 2005; 47(4):437-44. PubMed ID: 15971886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.
    Kamijo-Ikemori A; Sugaya T; Sekizuka A; Hirata K; Kimura K
    Nephrol Dial Transplant; 2009 Mar; 24(3):788-800. PubMed ID: 18854419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.
    Sasaki H; Kamijo-Ikemori A; Sugaya T; Yamashita K; Yokoyama T; Koike J; Sato T; Yasuda T; Kimura K
    Nephron Clin Pract; 2009; 112(3):c148-56. PubMed ID: 19390215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [L-type fatty acid binding protein (L-FABP) and kidney disease].
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Rinsho Byori; 2014 Feb; 62(2):163-70. PubMed ID: 24800492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Yasuda T; Hoshino S; Igarashi-Migitaka J; Hirata K; Kimura K
    Hypertension; 2012 Oct; 60(4):973-80. PubMed ID: 22926951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary fatty acid binding protein in renal disease.
    Kamijo-Ikemori A; Sugaya T; Kimura K
    Clin Chim Acta; 2006 Dec; 374(1-2):1-7. PubMed ID: 16860300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease.
    Kamijo A; Kimura K; Sugaya T; Yamanouchi M; Hikawa A; Hirano N; Hirata Y; Goto A; Omata M
    J Lab Clin Med; 2004 Jan; 143(1):23-30. PubMed ID: 14749682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity.
    Matsui K; Kamijo-Ikemorif A; Sugaya T; Yasuda T; Kimura K
    Am J Pathol; 2011 Mar; 178(3):1021-32. PubMed ID: 21356355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation.
    Ichikawa D; Kamijo-Ikemori A; Sugaya T; Shibagaki Y; Yasuda T; Katayama K; Hoshino S; Igarashi-Migitaka J; Hirata K; Kimura K
    Am J Physiol Renal Physiol; 2014 Mar; 306(6):F655-63. PubMed ID: 24431207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.